SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,090.44 |
| Enterprise Value ($M) | 1,007.04 |
| Book Value ($M) | 377.48 |
| Book Value / Share | 2.76 |
| Price / Book | 2.89 |
| NCAV ($M) | 273.43 |
| NCAV / Share | 2.00 |
| Price / NCAV | 3.99 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.01 |
| Return on Assets (ROA) | 0.01 |
| Return on Equity (ROE) | 0.02 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.17 |
| Current Ratio | 4.57 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 446.60 |
| Assets | 550.64 |
| Liabilities | 173.17 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 235.13 |
| Operating Income | 12.52 |
| Net Income | 5.75 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 44.39 |
| Cash from Investing | 39.26 |
| Cash from Financing | -49.09 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Tang Capital Management Llc | 7.30 | 38.73 | |
| 13G/A | Armistice Capital, Llc | 4.47 | -21.95 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 320,569 | 1,344,399 | 23.84 | |
| 193,302 | 824,255 | 23.45 | |
| 152,303 | 722,785 | 21.07 | |
| 185,323 | 845,091 | 21.93 | |
| 107,568 | 701,590 | 15.33 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ARDX – Ardelyx, Inc. | ATAI – Atai Life Sciences N.V. |
| ATXS – Astria Therapeutics, Inc. | AURA – Aura Biosciences, Inc. |
| AVBP – ArriVent BioPharma, Inc. |